The immunological and clinical effects of mutated ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors

BACKGROUND: Mutant Ras oncogenes produce proteins that are unique to cancer cells and represent attractive targets for vaccine therapy. We have shown previously that vaccinating cancer patients with mutant ras peptides is feasible and capable of inducing a specific immune response against the releva...

Descripción completa

Detalles Bibliográficos
Autores principales: Rahma, Osama E, Hamilton, J Michael, Wojtowicz, Malgorzata, Dakheel, Omar, Bernstein, Sarah, Liewehr, David J, Steinberg, Seth M, Khleif, Samir N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3942063/
https://www.ncbi.nlm.nih.gov/pubmed/24565030
http://dx.doi.org/10.1186/1479-5876-12-55

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3942063/
https://www.ncbi.nlm.nih.gov/pubmed/24565030
http://dx.doi.org/10.1186/1479-5876-12-55

Ejemplares similares